Global Patent Index - EP 0833620 B1

EP 0833620 B1 20021009 - FGFR3 AS A MARKER FOR MESENCHYMAL SKELETAL PROGENITOR CELLS

Title (en)

FGFR3 AS A MARKER FOR MESENCHYMAL SKELETAL PROGENITOR CELLS

Title (de)

FGFR3 ALS SIGNAL FÜR DIE VORLÄUFER DER MESENCHYMZELLEN DES SKELETTS

Title (fr)

FGFR3 UTILISE EN QUALITE DE MARQUEUR DE CELLULES PROGENITRICES MESENCHYMATEUSES DU SQUELETTE

Publication

EP 0833620 B1 20021009 (EN)

Application

EP 96917640 A 19960612

Priority

  • IL 9600010 W 19960612
  • US 13795 P 19950612

Abstract (en)

[origin: EP1342476A2] The present invention concerns fibroblast growth factor receptor 3 (FGFR3) as a novel marker for mesenchymal skeletal progenitor cells. By utilizing this novel marker it was possible both to identify and locate mesenchymal skeletal progenitor cells in a tissue, as well as to obtain a substantially pure culture of such cells. The pure culture of the mesenchymal skeletal progenitor cells may be used, optionally after various manipulations ex vivo, as an active ingredient in pharmaceutical compositions or implants for the purpose of bone and/or cartilage repair. FGFR3 may also be used as a marker for the identification and the localization of cartilage- and bone-derived tumors. Agents capable of binding to FGFR3 may also be used for targeting cytotoxic agents to cartillage- and bone-derived tumors.The present invention concerns fibroblast growth factor receptor 3 (FGFR3) as a novel marker for mesenchymal skeletal progenitor cells. By utilizing this novel marker it was possible both to identify and locate mesenchymal skeletal progenitor cells in a tissue, as well as to obtain a substantially pure culture of such cells. The pure culture of the mesenchymal skeletal progenitor cells may be used, optionally after various manipulations ex vivo, as an active ingredient in pharmaceutical compositions or implants for the purpose of bone and/or cartilage repair. FGFR3 may also be used as a marker for the identification and the localization of cartilage- and bone-derived tumors. Agents capable of binding to FGFR3 may also be used for targeting cytotoxic agents to cartillage- and bone-derived tumors.

IPC 1-7

A61K 9/22; A61K 39/395; C07K 16/00; C12P 21/08; C12N 5/00; G01N 33/558

IPC 8 full level

C12N 15/09 (2006.01); A01K 67/027 (2006.01); A61K 9/22 (2006.01); A61K 35/32 (2006.01); A61K 38/00 (2006.01); A61K 38/22 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61L 27/00 (2006.01); A61P 5/00 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07K 14/50 (2006.01); C07K 14/715 (2006.01); C07K 16/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C12N 5/00 (2006.01); C12P 21/08 (2006.01); C12Q 1/02 (2006.01); G01N 33/53 (2006.01); G01N 33/558 (2006.01); G01N 33/566 (2006.01); G01N 33/569 (2006.01); G01N 33/68 (2006.01); G01N 33/74 (2006.01); A61K 39/00 (2006.01)

CPC (source: EP US)

A61P 5/00 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07K 14/50 (2013.01 - EP US); C07K 16/2863 (2013.01 - EP US); G01N 33/53 (2013.01 - EP US); G01N 33/566 (2013.01 - EP US); G01N 33/56966 (2013.01 - EP US); G01N 33/6887 (2013.01 - EP US); G01N 33/74 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US); A61K 2039/505 (2013.01 - EP US); G01N 2333/50 (2013.01 - EP US); G01N 2333/9121 (2013.01 - EP US)

Citation (examination)

  • US 5226914 A 19930713 - CAPLAN ARNOLD I [US], et al
  • IWAMOTO M ET AL.: "Reduction in Basic Fibroblast Growth Factor Receptor is coupled with terminal differentiation of chondrocytes", J. BIOL. CHEM., vol. 266, no. 1, 5 January 1991 (1991-01-05), pages 461 - 467
  • SASSE J et al. "Expression of Fibroblast Growth Factor Receptors During Cartilage Differentiation", poster published on 27.-29.04.2000
  • NEVO Z et al. "The Manipulated Mesenchymal Stem Cells in Regenerated Skeletal Muscles", Cell Transplantantion, Vol. 7, Nr. 1 63-70, 1998
  • ROBINSON D et al. "Fibroblast Growth Factor Receptor-3 as a Marker for Precartilaginous Stem Cells", Clin. Orthopaedics and Related Research, Nr. 3673, S163-S175, 1999

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9641523 A1 19961227; AT E213590 T1 20020315; AT E225652 T1 20021015; AU 6014496 A 19970109; AU 6014596 A 19970109; AU 715996 B2 20000217; AU 721773 B2 20000713; CA 2223701 A1 19961227; CA 2223701 C 20100216; CA 2224229 A1 19961227; CN 1195982 A 19981014; DE 69619526 D1 20020404; DE 69619526 T2 20021031; DE 69624239 D1 20021114; DE 69624239 T2 20030710; DK 0833620 T3 20030113; DK 0836380 T3 20020422; EP 0833620 A1 19980408; EP 0833620 A4 19980506; EP 0833620 B1 20021009; EP 0836380 A1 19980422; EP 0836380 A4 19990331; EP 0836380 B1 20020227; EP 1342476 A2 20030910; EP 1342476 A3 20030917; ES 2173289 T3 20021016; ES 2183957 T3 20030401; IL 122472 A0 19980615; IL 122472 A 20031123; IL 122473 A0 19980615; IL 122473 A 20031123; JP 2004305221 A 20041104; JP 3673281 B2 20050720; JP H11507828 A 19990713; JP H11508358 A 19990721; US 2002193309 A1 20021219; US 6447783 B1 20020910; WO 9641620 A1 19961227

DOCDB simple family (application)

IL 9600011 W 19960612; AT 96917640 T 19960612; AT 96917641 T 19960612; AU 6014496 A 19960612; AU 6014596 A 19960612; CA 2223701 A 19960612; CA 2224229 A 19960612; CN 96194719 A 19960612; DE 69619526 T 19960612; DE 69624239 T 19960612; DK 96917640 T 19960612; DK 96917641 T 19960612; EP 02022340 A 19960612; EP 96917640 A 19960612; EP 96917641 A 19960612; ES 96917640 T 19960612; ES 96917641 T 19960612; IL 12247296 A 19960612; IL 12247396 A 19960612; IL 9600010 W 19960612; JP 2004192332 A 20040629; JP 50286997 A 19960612; JP 50287097 A 19960612; US 21235702 A 20020802; US 98103098 A 19980506